Coverstone, Edward D.
Bach, Richard G.
Chen, LiShiun
Bierut, Laura J.
Li, Allie Y.
Lenzini, Petra A.
O’Neill, Heidi C.
Spertus, John A.
Sucharov, Carmen C.
Stitzel, Jerry A.
Schilling, Joel D.
Cresci, Sharon http://orcid.org/0000-0002-5417-1054
Funding for this research was provided by:
National Institutes of Health (R01 NR013396, P50 HL077113, T32-HL07081-38, UL1TR000448, R01 DA025888, R01 DA036583)
Article History
Received: 6 June 2017
Accepted: 6 August 2018
First Online: 10 August 2018
Compliance with ethical standards
:
: Edward Coverstone: None. Richard G. Bach: Research Grants: Novartis, MyoKardia. Consultant (Clinical Event Committee activity only): Novo Nordisk, Pharmacosmos NA. LiShiun Chen: None. Laura J. Bierut: Copyrights/Patents: Listed as an inventor on Issued U.S. Patent 8080,371,“Markers for Addiction” covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. Allie Y. Li: None. Petra A. Lenzini: None. Heidi C. O'Neill: None. John A. Spertus: Research Grants: Eli Lilly, EveHeart, Genentech, Gilead. Consultant: St. Jude Medical, United Healthcare, Amgen, Genentech, Janssen. Copyrights/Patents: Seattle Angina Questionnaire, Kansas City Cardiomyopathy Questionnaire, Peripheral Artery Questionnaire, US Patents: 7643,969; 7,853,456; 12/965,656; 13/615,401. Carmen Sucharov: Scientific founder and shareholder, CoramiR Inc. and miRagen Inc. Jerry Stitzel: Research grants: Pfizer. Joel Schilling: None. Sharon Cresci: None.